{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:05:32Z","timestamp":1792605932295,"version":"4.5.0"},"reference-count":147,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T00:00:00Z","timestamp":1573430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T00:00:00Z","timestamp":1573430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81521063"],"award-info":[{"award-number":["81521063"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81701312"],"award-info":[{"award-number":["81701312"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Fentanyl is a powerful opioid anesthetic and analgesic, the use of which has caused an increasing public health threat in the United States and elsewhere. Fentanyl was initially approved and used for the treatment of moderate to severe pain, especially cancer pain. However, recent years have seen a growing concern that fentanyl and its analogs are widely synthesized in laboratories and adulterated with illicit supplies of heroin, cocaine, methamphetamine, and counterfeit pills, contributing to the exponential growth in the number of drug-related overdose deaths. This review summarizes the recent epidemic and evolution of illicit fentanyl use, its pharmacological mechanisms and side effects, and the potential clinical management and prevention of fentanyl-related overdoses. Because social, economic, and health problems that are related to the use of fentanyl and its analogs are growing, there is an urgent need to implement large-scale safe and effective harm reduction strategies to prevent fentanyl-related overdoses.<\/jats:p>","DOI":"10.1038\/s41398-019-0625-0","type":"journal-article","created":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T06:03:02Z","timestamp":1573452182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":217,"title":["The rising crisis of illicit fentanyl use, overdose, and potential therapeutic strategies"],"prefix":"10.1038","volume":"9","author":[{"given":"Ying","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongbo","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Zahid","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,11]]},"reference":[{"key":"625_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3109\/15563659509013752","volume":"33","author":"A Poklis","year":"1995","unstructured":"Poklis, A. Fentanyl: a review for clinical and analytical toxicologists. J. Toxicol. Clin. Toxicol. 33, 439\u2013447 (1995).","journal-title":"J. Toxicol. Clin. Toxicol."},{"key":"625_CR2","doi-asserted-by":"crossref","unstructured":"Clotz, M. A. & Nahata, M. C. Clinical uses of fentanyl, sufentanil, and alfentanil. Clin. Pharm. 10, 581\u2013593 (1991).","DOI":"10.1093\/ajhp\/48.9.2021"},{"key":"625_CR3","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1136\/jramc-2013-000227","volume":"160","author":"D Aldington","year":"2014","unstructured":"Aldington, D. & Jagdish, S. The fentanyl \u2018lozenge\u2019 story: from books to battlefield. J. R. Army Med. Corps 160, 102\u2013104 (2014).","journal-title":"J. R. Army Med. Corps"},{"key":"625_CR4","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.jpain.2014.08.010","volume":"15","author":"TH Stanley","year":"2014","unstructured":"Stanley, T. H. The fentanyl story. J. Pain 15, 1215\u20131226 (2014).","journal-title":"J. Pain"},{"key":"625_CR5","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s40265-017-0727-z","volume":"77","author":"SA Schug","year":"2017","unstructured":"Schug, S. A. & Ting, S. Fentanyl formulations in the management of pain: an update. Drugs 77, 747\u2013763 (2017).","journal-title":"Drugs"},{"issue":"2","key":"625_CR6","doi-asserted-by":"publisher","first-page":"13045J","DOI":"10.1520\/JFS13045J","volume":"36","author":"Gary L. Henderson","year":"1991","unstructured":"Henderson, G. L. Fentanyl-related deaths: demographics, circumstances, and toxicology of 112 cases. J. Forensic Sci. 36, 422\u2013433 (1991).","journal-title":"Journal of Forensic Sciences"},{"key":"625_CR7","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1001\/jama.1991.03460080081037","volume":"265","author":"J Hibbs","year":"1991","unstructured":"Hibbs, J., Perper, J. & Winek, C. L. An outbreak of designer drug-related deaths in Pennsylvania. JAMA 265, 1011\u20131013 (1991).","journal-title":"JAMA"},{"issue":"6408","key":"625_CR8","doi-asserted-by":"publisher","first-page":"eaau1184","DOI":"10.1126\/science.aau1184","volume":"361","author":"Hawre Jalal","year":"2018","unstructured":"Jalal, H. et al. Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016. Science 361, eaau1184 (2018).","journal-title":"Science"},{"key":"625_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.drugalcdep.2016.11.033","volume":"171","author":"J Suzuki","year":"2017","unstructured":"Suzuki, J. & El-Haddad, S. A review: fentanyl and non-pharmaceutical fentanyls. Drug Alcohol Depend. 171, 107\u2013116 (2017).","journal-title":"Drug Alcohol Depend."},{"key":"625_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.15585\/mmwr.mm6802a3","volume":"68","author":"C Colon-Berezin","year":"2019","unstructured":"Colon-Berezin, C., Nolan, M. L., Blachman-Forshay, J. & Paone, D. Overdose deaths involving fentanyl and fentanyl analogs\u2014New York City, 2000\u20132017. Morb. Mortal. Wkly Rep. 68, 37\u201340 (2019).","journal-title":"Morb. Mortal. Wkly Rep."},{"key":"625_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11524-018-00343-z","volume":"96","author":"ML Nolan","year":"2019","unstructured":"Nolan, M. L., Shamasunder, S., Colon-Berezin, C., Kunins, H. V. & Paone, D. Increased presence of fentanyl in cocaine-involved fatal overdoses: implications for prevention. J. Urban Health 96, 49\u201354 (2019).","journal-title":"J. Urban Health"},{"key":"625_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.2851","volume":"2","author":"L LaRue","year":"2019","unstructured":"LaRue, L. et al. Rate of fentanyl positivity among urine drug test results positive for cocaine or methamphetamine. JAMA Netw. Open 2, e192851 (2019).","journal-title":"JAMA Netw. Open"},{"key":"625_CR13","unstructured":"Hedegaard, H., Warner, M. & Minino, A. M. Drug overdose deaths in the United States, 1999\u20132016. NCHS Data Brief 294, 1\u20138 (2017)."},{"key":"625_CR14","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S2215-0366(18)30103-2","volume":"5","author":"B Pardo","year":"2018","unstructured":"Pardo, B. & Reuter, P. Facing fentanyl: should the USA consider trialling prescription heroin? Lancet Psychiatry 5, 613\u2013615 (2018).","journal-title":"Lancet Psychiatry"},{"key":"625_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1053\/j.semperi.2019.01.001","volume":"43","author":"J Lyden","year":"2019","unstructured":"Lyden, J. & Binswanger, I. A. The United States opioid epidemic. Semin. Perinatol. 43, 123\u2013131 (2019).","journal-title":"Semin. Perinatol."},{"key":"625_CR16","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1001\/jama.2018.2844","volume":"319","author":"CM Jones","year":"2018","unstructured":"JonesC. M., EinsteinE. B. & ComptonW. M. Changes in synthetic opioid involvement in drug overdose deaths in the United States, 2010\u20132016. JAMA 319, 1819\u20131821 (2018).","journal-title":"JAMA"},{"key":"625_CR17","doi-asserted-by":"crossref","unstructured":"Scholl, L., Seth, P., Kariisa, M., Wilson, N. & Baldwin, G. Drug and opioid-involved overdose deaths\u2014United States, 2013\u20132017. Morb. Mortal. Wkly Rep. 67, 1419\u20131427 (2018).","DOI":"10.15585\/mmwr.mm675152e1"},{"key":"625_CR18","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.2147\/JPR.S140320","volume":"10","author":"JS Ahn","year":"2017","unstructured":"Ahn, J. S. et al. Transdermal buprenorphine and fentanyl patches in cancer pain: a network systematic review. J. Pain Res. 10, 1963\u20131972 (2017).","journal-title":"J. Pain Res."},{"key":"625_CR19","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/10717540500394661","volume":"13","author":"K Mystakidou","year":"2006","unstructured":"Mystakidou, K., Katsouda, E., Parpa, E., Vlahos, L. & Tsiatas, M. L. Oral transmucosal fentanyl citrate: overview of pharmacological and clinical characteristics. Drug Deliv. 13, 269\u2013276 (2006).","journal-title":"Drug Deliv."},{"key":"625_CR20","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1080\/03007995.2017.1294559","volume":"33","author":"P Katz","year":"2017","unstructured":"Katz, P., Takyar, S., Palmer, P. & Liedgens, H. Sublingual, transdermal and intravenous patient-controlled analgesia for acute post-operative pain: systematic literature review and mixed treatment comparison. Curr. Med. Res. Opin. 33, 899\u2013910 (2017).","journal-title":"Curr. Med. Res. Opin."},{"key":"625_CR21","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1056\/NEJMp1615145","volume":"376","author":"RG Frank","year":"2017","unstructured":"Frank, R. G. & Pollack, H. A. Addressing the fentanyl threat to public health. N. Engl. J. Med. 376, 605\u2013607 (2017).","journal-title":"N. Engl. J. Med."},{"key":"625_CR22","doi-asserted-by":"crossref","unstructured":"Smialek, J. E., Levine, B., Chin, L., Wu, S. C. & Jenkins, A. J. A fentanyl epidemic in Maryland 1992. J. Forensic Sci. 39, 159\u2013164 (1994).","DOI":"10.1520\/JFS13581J"},{"key":"625_CR23","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s13181-012-0285-4","volume":"9","author":"DA Algren","year":"2013","unstructured":"Algren, D. A. et al. Fentanyl-associated fatalities among illicit drug users in Wayne County, Michigan (July 2005\u2013May 2006). J. Med. Toxicol. 9, 106\u2013115 (2013).","journal-title":"J. Med. Toxicol."},{"key":"625_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-018-0685-5","volume":"22","author":"PS Ostling","year":"2018","unstructured":"Ostling, P. S. et al. America\u2019s opioid epidemic: a comprehensive review and look into the rising crisis. Curr. Pain Headache Rep. 22, 32 (2018).","journal-title":"Curr. Pain Headache Rep."},{"key":"625_CR25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ypmed.2017.11.001","volume":"107","author":"B Fischer","year":"2018","unstructured":"Fischer, B., Vojtila, L. & Rehm, J. The \u2018fentanyl epidemic\u2019 in Canada\u2014some cautionary observations focusing on opioid-related mortality. Prev. Med. 107, 109\u2013113 (2018).","journal-title":"Prev. Med."},{"key":"625_CR26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.addbeh.2018.03.010","volume":"86","author":"P Phalen","year":"2018","unstructured":"Phalen, P., Ray, B., Watson, D. P., Huynh, P. & Greene, M. S. Fentanyl related overdose in Indianapolis: estimating trends using multilevel Bayesian models. Addict. Behav. 86, 4\u201310 (2018).","journal-title":"Addict. Behav."},{"key":"625_CR27","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1001\/jamapsychiatry.2017.4432","volume":"75","author":"AA Jones","year":"2018","unstructured":"Jones, A. A. et al. Rapid change in fentanyl prevalence in a community-based, high-risk sample. JAMA Psychiatry 75, 298\u2013300 (2018).","journal-title":"JAMA Psychiatry"},{"key":"625_CR28","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.drugalcdep.2017.07.018","volume":"179","author":"A Roxburgh","year":"2017","unstructured":"Roxburgh, A. et al. Trends in heroin and pharmaceutical opioid overdose deaths in Australia. Drug Alcohol Depend. 179, 291\u2013298 (2017).","journal-title":"Drug Alcohol Depend."},{"key":"625_CR29","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.scijus.2018.04.004","volume":"58","author":"HE McKeown","year":"2018","unstructured":"McKeown, H. E., Rook, T. J., Pearson, J. R. & Jones, O. A. H. Is Australia ready for fentanyl? Sci. Justice 58, 366\u2013371 (2018).","journal-title":"Sci. Justice"},{"key":"625_CR30","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.15585\/mmwr.mm6643e1","volume":"66","author":"JK O\u2019Donnell","year":"2017","unstructured":"O\u2019Donnell, J. K., Halpin, J., Mattson, C. L., Goldberger, B. A. & Gladden, R. M. Deaths involving fentanyl, fentanyl analogs, and U-47700\u201410 states, July\u2013December 2016. Morb. Mortal. Wkly Rep. 66, 1197\u20131202 (2017).","journal-title":"Morb. Mortal. Wkly Rep."},{"key":"625_CR31","doi-asserted-by":"publisher","first-page":"k3207","DOI":"10.1136\/bmj.k3207","volume":"362","author":"T Gomes","year":"2018","unstructured":"Gomes, T. et al. Contributions of prescribed and non-prescribed opioids to opioid related deaths: population based cohort study in Ontario, Canada. BMJ 362, k3207 (2018).","journal-title":"BMJ"},{"key":"625_CR32","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.drugalcdep.2019.01.045","volume":"198","author":"R Daniulaityte","year":"2019","unstructured":"Daniulaityte, R. et al. Trends in fentanyl and fentanyl analogue-related overdose deaths - Montgomery County, Ohio, 2015\u20132017. Drug Alcohol Depend. 198, 116\u2013120 (2019).","journal-title":"Drug Alcohol Depend."},{"key":"625_CR33","doi-asserted-by":"crossref","unstructured":"Bijral, P., Hayhurst, K. P., Bird, S. M. & Millar, T. Prevalence of recent fentanyl use among treated users of illicit opioids in England: based on piloted urine drug screens. Clin. Toxicol. 57, 368\u2013371 (2019).","DOI":"10.1080\/15563650.2018.1527927"},{"key":"625_CR34","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.forsciint.2017.11.036","volume":"282","author":"L Hikin","year":"2018","unstructured":"Hikin, L., Smith, P. R., Ringland, E., Hudson, S. & Morley, S. R. Multiple fatalities in the North of England associated with synthetic fentanyl analogue exposure: detection and quantitation a case series from early 2017. Forensic Sci. Int. 282, 179\u2013183 (2018).","journal-title":"Forensic Sci. Int."},{"key":"625_CR35","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.2105\/AJPH.2018.304694","volume":"108","author":"J Blachman-Forshay","year":"2018","unstructured":"Blachman-Forshay, J., Nolan, M. L., McAteer, J. M. & Paone, D. Estimating the risk of exposure to fentanyl in New York city: testing drug residue in used syringes. Am. J. Public Health 108, 1666\u20131668 (2018).","journal-title":"Am. J. Public Health"},{"key":"625_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2017.10.020","volume":"183","author":"K Hayashi","year":"2018","unstructured":"Hayashi, K. et al. Substance use patterns associated with recent exposure to fentanyl among people who inject drugs in Vancouver, Canada: a cross-sectional urine toxicology screening study. Drug Alcohol Depend. 183, 1\u20136 (2018).","journal-title":"Drug Alcohol Depend."},{"key":"625_CR37","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12954-018-0240-z","volume":"15","author":"JN Park","year":"2018","unstructured":"Park, J. N., Weir, B. W., Allen, S. T., Chaulk, P. & Sherman, S. G. Fentanyl-contaminated drugs and non-fatal overdose among people who inject drugs in Baltimore. Md. Harm Reduct. J. 15, 34 (2018).","journal-title":"Md. Harm Reduct. J."},{"key":"625_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-015-2604-6","volume":"15","author":"A Uuskula","year":"2015","unstructured":"Uuskula, A. et al. Non-fatal overdoses and related risk factors among people who inject drugs in St. Petersburg, Russia and Kohtla-Jarve, Estonia. BMC Public Health 15, 1255 (2015).","journal-title":"BMC Public Health"},{"key":"625_CR39","doi-asserted-by":"crossref","unstructured":"Geddes, L., Iversen, J., Memedovic, S. & Maher, L. Intravenous fentanyl use among people who inject drugs in Australia. Drug Alcohol Rev. 37(Suppl. 1), S314\u2013S322 (2018).","DOI":"10.1111\/dar.12668"},{"key":"625_CR40","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.drugpo.2016.08.004","volume":"37","author":"J Latimer","year":"2016","unstructured":"Latimer, J., Ling, S., Flaherty, I., Jauncey, M. & Salmon, A. M. Risk of fentanyl overdose among clients of the Sydney Medically Supervised Injecting Centre. Int J. Drug Policy 37, 111\u2013114 (2016).","journal-title":"Int J. Drug Policy"},{"key":"625_CR41","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1001\/jama.2017.15971","volume":"318","author":"D Dowell","year":"2017","unstructured":"Dowell, D., Noonan, R. K. & Houry, D. Underlying factors in drug overdose deaths. JAMA 318, 2295\u20132296 (2017).","journal-title":"JAMA"},{"key":"625_CR42","doi-asserted-by":"crossref","unstructured":"Giorgetti, A., Centola, C. & Giorgetti, R. Fentanyl novel derivative-related deaths. Hum. Psychopharmacol. 32, e2605 (2017).","DOI":"10.1002\/hup.2605"},{"key":"625_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-015-0088-4","volume":"12","author":"A Amlani","year":"2015","unstructured":"Amlani, A. et al. Why the FUSS (Fentanyl Urine Screen Study)? A cross-sectional survey to characterize an emerging threat to people who use drugs in British Columbia, Canada. Harm Reduct. J. 12, 54 (2015).","journal-title":"Harm Reduct. J."},{"key":"625_CR44","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jsat.2017.01.004","volume":"75","author":"CL Arfken","year":"2017","unstructured":"Arfken, C. L., Suchanek, J. & Greenwald, M. K. Characterizing fentanyl use in methadone-maintained clients. J. Subst. Abus. Treat. 75, 17\u201321 (2017).","journal-title":"J. Subst. Abus. Treat."},{"key":"625_CR45","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.drugalcdep.2017.04.004","volume":"177","author":"TJ Cicero","year":"2017","unstructured":"Cicero, T. J., Ellis, M. S. & Kasper, Z. A. Increases in self-reported fentanyl use among a population entering drug treatment: the need for systematic surveillance of illicitly manufactured opioids. Drug Alcohol Depend. 177, 101\u2013103 (2017).","journal-title":"Drug Alcohol Depend."},{"key":"625_CR46","doi-asserted-by":"publisher","unstructured":"Strike, C. & Watson, T. M. Losing the uphill battle? Emergent harm reduction interventions and barriers during the opioid overdose crisis in Canada. Int. J. Drug Policy. https:\/\/doi.org\/10.1016\/j.drugpo.2019.02.005 (2019).","DOI":"10.1016\/j.drugpo.2019.02.005"},{"key":"625_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-018-0213-2","volume":"15","author":"MS Krieger","year":"2018","unstructured":"Krieger, M. S. et al. High willingness to use rapid fentanyl test strips among young adults who use drugs. Harm Reduct. J. 15, 7 (2018).","journal-title":"Harm Reduct. J."},{"key":"625_CR48","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.drugalcdep.2017.12.026","volume":"185","author":"MC Kennedy","year":"2018","unstructured":"Kennedy, M. C. et al. Willingness to use drug checking within future supervised injection services among people who inject drugs in a mid-sized Canadian city. Drug Alcohol Depend. 185, 248\u2013252 (2018).","journal-title":"Drug Alcohol Depend."},{"key":"625_CR49","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1097\/FTD.0000000000000564","volume":"40","author":"MS Bergh","year":"2018","unstructured":"Bergh, M. S., Bogen, I. L., Wilson, S. R. & Oiestad, A. M. L. Addressing the fentanyl analogue epidemic by multiplex UHPLC\u2013MS\/MS analysis of whole blood. Ther. Drug Monit. 40, 738\u2013748 (2018).","journal-title":"Ther. Drug Monit."},{"key":"625_CR50","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1080\/00952990.2018.1550652","volume":"45","author":"JJ Palamar","year":"2019","unstructured":"Palamar, J. J. et al. Testing hair for fentanyl exposure: a method to inform harm reduction behavior among individuals who use heroin. Am. J. Drug Alcohol Abus. 45, 90\u201396 (2019).","journal-title":"Am. J. Drug Alcohol Abus."},{"key":"625_CR51","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1093\/jat\/bky035","volume":"42","author":"MF Fogarty","year":"2018","unstructured":"Fogarty, M. F., Papsun, D. M. & Logan, B. K. Analysis of fentanyl and 18 novel fentanyl analogs and metabolites by LC\u2013MS\u2013MS, and report of fatalities associated with methoxyacetylfentanyl and cyclopropylfentanyl. J. Anal. Toxicol. 42, 592\u2013604 (2018).","journal-title":"J. Anal. Toxicol."},{"key":"625_CR52","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s13181-017-0632-6","volume":"13","author":"MK Griswold","year":"2017","unstructured":"Griswold, M. K. et al. A novel oral fluid assay (LC-QTOF-MS) for the detection of fentanyl and clandestine opioids in oral fluid after reported heroin overdose. J. Med. Toxicol. 13, 287\u2013292 (2017).","journal-title":"J. Med. Toxicol."},{"key":"625_CR53","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.forsciint.2019.04.019","volume":"300","author":"DJ Angelini","year":"2019","unstructured":"Angelini, D. J. et al. Evaluation of a lateral flow immunoassay for the detection of the synthetic opioid fentanyl. Forensic Sci. Int. 300, 75\u201381 (2019).","journal-title":"Forensic Sci. Int."},{"issue":"9","key":"625_CR54","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3390\/brainsci8090170","volume":"8","author":"Paolo Frisoni","year":"2018","unstructured":"Frisoni, P. et al. Novel synthetic opioids: the pathologist\u2019s point of view. Brain Sci. 8, E170 (2018).","journal-title":"Brain Sciences"},{"key":"625_CR55","first-page":"309","volume":"54","author":"NJ Gaskey","year":"1986","unstructured":"Gaskey, N. J., Ferriero, L., Pournaras, L. & Seecof, J. Use of fentanyl markedly increases nausea and vomiting in gynecological short stay patients. AANA J. 54, 309\u2013311 (1986).","journal-title":"AANA J."},{"key":"625_CR56","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1756-9966-29-67","volume":"29","author":"Q Yang","year":"2010","unstructured":"Yang, Q. et al. Efficacy and adverse effects of transdermal fentanyl and sustained-release oral morphine in treating moderate-severe cancer pain in Chinese population: a systematic review and meta-analysis. J. Exp. Clin. Cancer Res. 29, 67 (2010).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"625_CR57","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/S0006-2952(03)00085-6","volume":"65","author":"G Wei","year":"2003","unstructured":"Wei, G., Moss, J. & Yuan, C. S. Opioid-induced immunosuppression: is it centrally mediated or peripherally mediated? Biochem. Pharm. 65, 1761\u20131766 (2003).","journal-title":"Biochem. Pharm."},{"key":"625_CR58","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/SPC.0b013e3282f5272e","volume":"2","author":"P Sacerdote","year":"2008","unstructured":"Sacerdote, P. Opioid-induced immunosuppression. Curr. Opin. Support. Palliat. Care 2, 14\u201318 (2008).","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"625_CR59","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/j.1533-2500.2008.00204.x","volume":"8","author":"J Pergolizzi","year":"2008","unstructured":"Pergolizzi, J. et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain. Pr. 8, 287\u2013313 (2008).","journal-title":"Pain. Pr."},{"key":"625_CR60","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2217\/pmt.12.22","volume":"2","author":"RF Wolff","year":"2012","unstructured":"Wolff, R. F. et al. Systematic review of adverse events of buprenorphine patch versus fentanyl patch in patients with chronic moderate-to-severe pain. Pain Manag. 2, 351\u2013362 (2012).","journal-title":"Pain Manag."},{"key":"625_CR61","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1212\/01.WNL.0000147326.21231.74","volume":"63","author":"R Gil-Gouveia","year":"2004","unstructured":"Gil-Gouveia, R., Wilkinson, P. A. & Kaube, H. Severe hemiplegic migraine attack precipitated by fentanyl sedation for esophagogastroscopy. Neurology 63, 2446\u20132447 (2004).","journal-title":"Neurology"},{"key":"625_CR62","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s10198-008-0134-1","volume":"10","author":"B Hass","year":"2009","unstructured":"Hass, B. et al. Cost-effectiveness of strong opioids focussing on the long-term effects of opioid-related fractures: a model approach. Eur. J. Health Econ. 10, 309\u2013321 (2009).","journal-title":"Eur. J. Health Econ."},{"key":"625_CR63","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0304-3959(96)03238-1","volume":"69","author":"E Bruera","year":"1997","unstructured":"Bruera, E. & Pereira, J. Acute neuropsychiatric findings in a patient receiving fentanyl for cancer pain. Pain 69, 199\u2013201 (1997).","journal-title":"Pain"},{"key":"625_CR64","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neubiorev.2018.12.005","volume":"106","author":"SD Comer","year":"2019","unstructured":"Comer, S. D. & Cahill, C. M. Fentanyl: receptor pharmacology, abuse potential, and implications for treatment. Neurosci. Biobehav. Rev. 106, 49\u201357 (2019).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"625_CR65","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1001\/jamapsychiatry.2018.3126","volume":"76","author":"ND Volkow","year":"2019","unstructured":"Volkow, N. D., Jones, E. B., Einstein, E. B. & Wargo, E. M. Prevention and treatment of opioid misuse and addiction: a review. JAMA Psychiatry 76, 208\u2013216 (2019).","journal-title":"JAMA Psychiatry"},{"key":"625_CR66","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3389\/fphar.2019.00046","volume":"10","author":"F Schifano","year":"2019","unstructured":"Schifano, F., Chiappini, S., Corkery, J. M. & Guirguis, A. Assessing the 2004\u20132018 fentanyl misusing issues reported to an international range of adverse reporting systems. Front. Pharm. 10, 46 (2019).","journal-title":"Front. Pharm."},{"key":"625_CR67","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/pm\/pnx038","volume":"19","author":"PA Nadpara","year":"2018","unstructured":"Nadpara, P. A. et al. Risk factors for serious prescription opioid-induced respiratory depression or overdose: comparison of commercially insured and veterans health affairs populations. Pain Med. 19, 79\u201396 (2018).","journal-title":"Pain Med."},{"key":"625_CR68","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.tips.2018.09.006","volume":"39","author":"MH Baumann","year":"2018","unstructured":"Baumann, M. H., Kopajtic, T. A. & Madras, B. K. Pharmacological research as a key component in mitigating the opioid overdose crisis. Trends Pharm. Sci. 39, 995\u2013998 (2018).","journal-title":"Trends Pharm. Sci."},{"key":"625_CR69","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/0024-3205(93)90152-S","volume":"52","author":"JC Chen","year":"1993","unstructured":"Chen, J. C., Smith, E. R., Cahill, M., Cohen, R. & Fishman, J. B. The opioid receptor binding of dezocine, morphine, fentanyl, butorphanol and nalbuphine. Life Sci. 52, 389\u2013396 (1993).","journal-title":"Life Sci."},{"key":"625_CR70","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/j.1399-6576.1986.tb02437.x","volume":"30","author":"HB Andersen","year":"1986","unstructured":"Andersen, H. B., Christensen, B., Findlay, J. W. & Jansen, J. A. Pharmacokinetics of intravenous, intrathecal and epidural morphine and fentanyl in the goat. Acta Anaesthesiol. Scand. 30, 393\u2013399 (1986).","journal-title":"Acta Anaesthesiol. Scand."},{"key":"625_CR71","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/0014-2999(91)90512-O","volume":"197","author":"Y Jang","year":"1991","unstructured":"Jang, Y. & Yoburn, B. C. Evaluation of receptor mechanism mediating fentanyl analgesia and toxicity. Eur. J. Pharm. 197, 135\u2013141 (1991).","journal-title":"Eur. J. Pharm."},{"key":"625_CR72","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1124\/mol.118.114751","volume":"95","author":"JN Tschirhart","year":"2019","unstructured":"Tschirhart, J. N., Li, W., Guo, J. & Zhang, S. Blockade of the human ether a-go-go-related gene (hERG) potassium channel by fentanyl. Mol. Pharm. 95, 386\u2013397 (2019).","journal-title":"Mol. Pharm."},{"key":"625_CR73","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.neuropharm.2019.02.008","volume":"151","author":"EA Kiyatkin","year":"2019","unstructured":"Kiyatkin, E. A. Respiratory depression and brain hypoxia induced by opioid drugs: morphine, oxycodone, heroin, and fentanyl. Neuropharmacology 151, 219\u2013226 (2019).","journal-title":"Neuropharmacology"},{"key":"625_CR74","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1093\/bja\/aei145","volume":"94","author":"A Dahan","year":"2005","unstructured":"Dahan, A. et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br. J. Anaesth. 94, 825\u2013834 (2005).","journal-title":"Br. J. Anaesth."},{"key":"625_CR75","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/npp.2017.181","volume":"43","author":"E Solis Jr.","year":"2018","unstructured":"Solis, E. Jr., Cameron-Burr, K. T., Shaham, Y. & Kiyatkin, E. A. Fentanyl-induced brain hypoxia triggers brain hyperglycemia and biphasic changes in brain temperature. Neuropsychopharmacology 43, 810\u2013819 (2018).","journal-title":"Neuropsychopharmacology"},{"key":"625_CR76","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1056\/NEJMc1716355","volume":"378","author":"JA Barash","year":"2018","unstructured":"Barash, J. A. et al. Acute amnestic syndrome associated with fentanyl overdose. N. Engl. J. Med. 378, 1157\u20131158 (2018).","journal-title":"N. Engl. J. Med."},{"key":"625_CR77","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1213\/00000539-199612000-00029","volume":"83","author":"WA Kofke","year":"1996","unstructured":"Kofke, W. A., Garman, R. H., Stiller, R. L., Rose, M. E. & Garman, R. Opioid neurotoxicity: fentanyl dose-response effects in rats. Anesth. Analg. 83, 1298\u20131306 (1996).","journal-title":"Anesth. Analg."},{"key":"625_CR78","doi-asserted-by":"publisher","first-page":"662","DOI":"10.7326\/L18-0411","volume":"169","author":"UB Duru","year":"2018","unstructured":"Duru, U. B. et al. An unusual amnestic syndrome associated with combined fentanyl and cocaine use. Ann. Intern. Med. 169, 662\u2013663 (2018).","journal-title":"Ann. Intern. Med."},{"key":"625_CR79","doi-asserted-by":"publisher","first-page":"E337","DOI":"10.1503\/cmaj.181291","volume":"191","author":"RG Taylor","year":"2019","unstructured":"Taylor, R. G., Budhram, A., Lee, D. H. & Mirsattari, S. M. Opioid-associated amnestic syndrome observed with fentanyl patch use. CMAJ 191, E337\u2013E339 (2019).","journal-title":"CMAJ"},{"key":"625_CR80","doi-asserted-by":"crossref","unstructured":"Solis, E., Jr., Cameron-Burr, K. T. & Kiyatkin, E. A. Heroin contaminated with fentanyl dramatically enhances brain hypoxia and induces brain hypothermia. eNeuro 4, ENEURO.0323\u201317.2017 (2017).","DOI":"10.1523\/ENEURO.0323-17.2017"},{"key":"625_CR81","first-page":"464","volume":"199","author":"MH Harper","year":"1976","unstructured":"Harper, M. H., Hickey, R. F., Cromwell, T. H. & Linwood, S. The magnitude and duration of respiratory depression produced by fentanyl and fentanyl plus droperidol in man. J. Pharm. Exp. Ther. 199, 464\u2013468 (1976).","journal-title":"J. Pharm. Exp. Ther."},{"key":"625_CR82","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1109\/TBME.2004.827344","volume":"51","author":"E Magosso","year":"2004","unstructured":"Magosso, E., Ursino, M. & van Oostrom, J. H. Opioid-induced respiratory depression: a mathematical model for fentanyl. IEEE Trans. Biomed. Eng. 51, 1115\u20131128 (2004).","journal-title":"IEEE Trans. Biomed. Eng."},{"key":"625_CR83","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1097\/00003246-199410000-00012","volume":"22","author":"AM Goetz","year":"1994","unstructured":"Goetz, A. M. et al. Adult respiratory distress syndrome associated with epidural fentanyl infusion. Crit. Care Med. 22, 1579\u20131583 (1994).","journal-title":"Crit. Care Med."},{"key":"625_CR84","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/0014-2999(96)00571-7","volume":"312","author":"SW Chen","year":"1996","unstructured":"Chen, S. W., Maguire, P. A., Davies, M. F., Beatty, M. F. & Loew, G. H. Evidence for mu1-opioid receptor involvement in fentanyl-mediated respiratory depression. Eur. J. Pharm. 312, 241\u2013244 (1996).","journal-title":"Eur. J. Pharm."},{"key":"625_CR85","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1097\/ALN.0000000000002676","volume":"130","author":"J Ren","year":"2019","unstructured":"Ren, J., Ding, X. & Greer, J. J. Activating alpha4beta2 nicotinic acetylcholine receptors alleviates fentanyl-induced respiratory depression in rats. Anesthesiology 130, 1017\u20131031 (2019).","journal-title":"Anesthesiology"},{"key":"625_CR86","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/ALN.0000000000000367","volume":"121","author":"M Roozekrans","year":"2014","unstructured":"Roozekrans, M. et al. Two studies on reversal of opioid-induced respiratory depression by BK-channel blocker GAL021 in human volunteers. Anesthesiology 121, 459\u2013468 (2014).","journal-title":"Anesthesiology"},{"key":"625_CR87","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1097\/ALN.0000000000002184","volume":"128","author":"A Dahan","year":"2018","unstructured":"Dahan, A. et al. Averting opioid-induced respiratory depression without affecting analgesia. Anesthesiology 128, 1027\u20131037 (2018).","journal-title":"Anesthesiology"},{"key":"625_CR88","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1097\/ALN.0000000000000844","volume":"123","author":"FJ Golder","year":"2015","unstructured":"Golder, F. J. et al. Identification and characterization of GAL-021 as a novel breathing control modulator. Anesthesiology 123, 1093\u20131104 (2015).","journal-title":"Anesthesiology"},{"key":"625_CR89","doi-asserted-by":"crossref","unstructured":"Oden, R. V. & Karagianes, T. G. Postoperative myocardial ischemia possibly masked by epidural fentanyl analgesia. Anesthesiology 74, 941\u2013943 (1991).","DOI":"10.1097\/00000542-199105000-00023"},{"key":"625_CR90","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1097\/00000542-198709000-00033","volume":"67","author":"JR Blair","year":"1987","unstructured":"Blair, J. R., Pruett, J. K., Crumrine, R. S. & Balser, J. J. Prolongation of QT interval in association with the administration of large doses of opiates. Anesthesiology 67, 442\u2013443 (1987).","journal-title":"Anesthesiology"},{"key":"625_CR91","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1213\/00000539-198002000-00018","volume":"59","author":"JC Hilgenberg","year":"1980","unstructured":"Hilgenberg, J. C. & Johantgen, W. C. Bradycardia after intravenous fentanyl during subarachnoid anesthesia. Anesth. Analg. 59, 162\u2013163 (1980).","journal-title":"Anesth. Analg."},{"key":"625_CR92","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s10557-018-6835-5","volume":"32","author":"M Zuin","year":"2018","unstructured":"Zuin, M., Rigatelli, G. & Roncon, L. Use of fentanyl during percutaneous coronary interventions: safety and drawbacks. Cardiovasc. Drugs Ther. 32, 625\u2013632 (2018).","journal-title":"Cardiovasc. Drugs Ther."},{"key":"625_CR93","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1161\/CIRCULATIONAHA.117.031678","volume":"137","author":"JW McEvoy","year":"2018","unstructured":"McEvoy, J. W. et al. Effect of intravenous fentanyl on ticagrelor absorption and platelet inhibition among patients undergoing percutaneous coronary intervention: the PACIFY randomized clinical trial (platelet aggregation with ticagrelor inhibition and fentanyl). Circulation 137, 307\u2013309 (2018).","journal-title":"Circulation"},{"key":"625_CR94","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cct.2017.11.011","volume":"64","author":"K Ibrahim","year":"2018","unstructured":"Ibrahim, K. et al. Effect of intravenous fentanyl on ticagrelor absorption and platelet inhibition among patients undergoing percutaneous coronary intervention: design, rationale, and sample characteristics of the PACIFY randomized trial. Contemp. Clin. Trials 64, 8\u201312 (2018).","journal-title":"Contemp. Clin. Trials"},{"key":"625_CR95","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.legalmed.2016.05.006","volume":"21","author":"I Takase","year":"2016","unstructured":"Takase, I., Koizumi, T., Fujimoto, I., Yanai, A. & Fujimiya, T. An autopsy case of acetyl fentanyl intoxication caused by insufflation of \u2018designer drugs\u2019. Leg. Med. 21, 38\u201344 (2016).","journal-title":"Leg. Med."},{"key":"625_CR96","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/jat\/bkw048","volume":"40","author":"J Poklis","year":"2016","unstructured":"Poklis, J. et al. Two fatal intoxications involving butyryl fentanyl. J. Anal. Toxicol. 40, 703\u2013708 (2016).","journal-title":"J. Anal. Toxicol."},{"key":"625_CR97","first-page":"982","volume":"82","author":"H Tsuchida","year":"1996","unstructured":"Tsuchida, H., Schubert, A., Estafanous, F. G., Brum, J. M. & Murray, P. A. Sigma receptor activation does not mediate fentanyl-induced attenuation of muscarinic coronary contraction. Anesth. Analg. 82, 982\u2013987 (1996).","journal-title":"Anesth. Analg."},{"key":"625_CR98","doi-asserted-by":"publisher","first-page":"123","DOI":"10.5055\/jom.2008.0017","volume":"4","author":"S Mitra","year":"2008","unstructured":"Mitra, S. Opioid-induced hyperalgesia: pathophysiology and clinical implications. J. Opioid Manag. 4, 123\u2013130 (2008).","journal-title":"J. Opioid Manag."},{"key":"625_CR99","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0304-3959(02)00422-0","volume":"100","author":"J Mao","year":"2002","unstructured":"Mao, J. Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain 100, 213\u2013217 (2002).","journal-title":"Pain"},{"key":"625_CR100","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177412","volume":"12","author":"Z Li","year":"2017","unstructured":"Li, Z. et al. CaMKIIalpha may modulate fentanyl-induced hyperalgesia via a CeLC-PAG-RVM-spinal cord descending facilitative pain pathway in rats. PLoS ONE 12, e0177412 (2017).","journal-title":"PLoS ONE"},{"key":"625_CR101","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jpain.2016.10.013","volume":"18","author":"Z Li","year":"2017","unstructured":"Li, Z. et al. Activation of the extracellular signal-regulated kinase in the amygdale modulates fentanyl-induced hypersensitivity in rats. J. Pain 18, 188\u2013199 (2017).","journal-title":"J. Pain"},{"key":"625_CR102","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/10550887.2012.694598","volume":"31","author":"G Bart","year":"2012","unstructured":"Bart, G. Maintenance medication for opiate addiction: the foundation of recovery. J. Addict. Dis. 31, 207\u2013225 (2012).","journal-title":"J. Addict. Dis."},{"key":"625_CR103","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1177\/1060028019828954","volume":"53","author":"B Doughty","year":"2019","unstructured":"Doughty, B., Morgenson, D. & Brooks, T. Lofexidine: a newly FDA-approved, nonopioid treatment for opioid withdrawal. Ann. Pharmacother. 53, 746\u2013753 (2019).","journal-title":"Ann. Pharmacother."},{"key":"625_CR104","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.drugalcdep.2017.02.020","volume":"176","author":"CW Gorodetzky","year":"2017","unstructured":"Gorodetzky, C. W. et al. A phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal. Drug Alcohol Depend. 176, 79\u201388 (2017).","journal-title":"Drug Alcohol Depend."},{"key":"625_CR105","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-018-0271-5","volume":"15","author":"MW Kinshella","year":"2018","unstructured":"Kinshella, M. W., Gauthier, T. & Lysyshyn, M. Rigidity, dyskinesia and other atypical overdose presentations observed at a supervised injection site, Vancouver, Canada. Harm. Reduct. J. 15, 64 (2018).","journal-title":"Harm. Reduct. J."},{"key":"625_CR106","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.drugalcdep.2018.09.006","volume":"193","author":"S Mayer","year":"2018","unstructured":"Mayer, S. et al. Characterizing fentanyl-related overdoses and implications for overdose response: findings from a rapid ethnographic study in Vancouver, Canada. Drug Alcohol Depend. 193, 69\u201374 (2018).","journal-title":"Drug Alcohol Depend."},{"key":"625_CR107","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1111\/bcp.13346","volume":"84","author":"CN Floyd","year":"2018","unstructured":"Floyd, C. N. & Warren, J. B. Opioids out of control. Br. J. Clin. Pharm. 84, 813\u2013815 (2018).","journal-title":"Br. J. Clin. Pharm."},{"key":"625_CR108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.annemergmed.2018.01.054","volume":"72","author":"FX Scheuermeyer","year":"2018","unstructured":"Scheuermeyer, F. X. et al. Safety of a brief emergency department observation protocol for patients with presumed fentanyl overdose. Ann. Emerg. Med. 72, 1\u20138 e1 (2018).","journal-title":"Ann. Emerg. Med."},{"key":"625_CR109","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.drugalcdep.2018.07.019","volume":"192","author":"AC Stone","year":"2018","unstructured":"Stone, A. C., Carroll, J. J., Rich, J. D. & Green, T. C. Methadone maintenance treatment among patients exposed to illicit fentanyl in Rhode Island: safety, dose, retention, and relapse at 6 months. Drug Alcohol Depend. 192, 94\u201397 (2018).","journal-title":"Drug Alcohol Depend."},{"key":"625_CR110","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41380-018-0329-5","volume":"24","author":"SA Pendergrass","year":"2019","unstructured":"Pendergrass, S. A., Crist, R. C., Jones, L. K., Hoch, J. R. & Berrettini, W. H. The importance of buprenorphine research in the opioid crisis. Mol. Psychiatry 24, 626\u2013632 (2019).","journal-title":"Mol. Psychiatry"},{"key":"625_CR111","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/ADM.0000000000000486","volume":"13","author":"SE Wakeman","year":"2019","unstructured":"Wakeman, S. E. et al. Impact of fentanyl use on buprenorphine treatment retention and opioid abstinence. J. Addict. Med. 13, 253\u2013257 (2019).","journal-title":"J. Addict. Med."},{"key":"625_CR112","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s002130000620","volume":"154","author":"EA Walker","year":"2001","unstructured":"Walker, E. A. & Young, A. M. Differential tolerance to antinociceptive effects of mu opioids during repeated treatment with etonitazene, morphine, or buprenorphine in rats. Psychopharmacology 154, 131\u2013142 (2001).","journal-title":"Psychopharmacology"},{"key":"625_CR113","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1124\/jpet.102.047068","volume":"305","author":"AC Barrett","year":"2003","unstructured":"Barrett, A. C., Smith, E. S. & Picker, M. J. Use of irreversible antagonists to determine the relative efficacy of mu-opioids in a pigeon drug discrimination procedure: comparison of beta-funaltrexamine and clocinnamox. J. Pharm. Exp. Ther. 305, 1061\u20131070 (2003).","journal-title":"J. Pharm. Exp. Ther."},{"key":"625_CR114","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0376-8716(02)00331-9","volume":"70","author":"SS Negus","year":"2003","unstructured":"Negus, S. S., Brandt, M. R., Gatch, M. B. & Mello, N. K. Effects of heroin and its metabolites on schedule-controlled responding and thermal nociception in rhesus monkeys: sensitivity to antagonism by quadazocine, naltrindole and beta-funaltrexamine. Drug Alcohol Depend. 70, 17\u201327 (2003).","journal-title":"Drug Alcohol Depend."},{"key":"625_CR115","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0376-8716(00)00166-6","volume":"62","author":"G Winger","year":"2001","unstructured":"Winger, G. & Woods, J. H. The effects of chronic morphine on behavior reinforced by several opioids or by cocaine in rhesus monkeys. Drug Alcohol Depend. 62, 181\u2013189 (2001).","journal-title":"Drug Alcohol Depend."},{"issue":"5","key":"625_CR116","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/add.14522","volume":"114","author":"Adam Bisaga","year":"2019","unstructured":"Bisaga, A. What should clinicians do as fentanyl replaces heroin? Addiction. https:\/\/doi.org\/10.1111\/add.14522 (2019).","journal-title":"Addiction"},{"key":"625_CR117","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.forsciint.2018.05.042","volume":"289","author":"K Kuczynska","year":"2018","unstructured":"Kuczynska, K., Grzonkowski, P., Kacprzak, L. & Zawilska, J. B. Abuse of fentanyl: an emerging problem to face. Forensic Sci. Int. 289, 207\u2013214 (2018).","journal-title":"Forensic Sci. Int."},{"key":"625_CR118","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.drugpo.2017.06.005","volume":"46","author":"N Fairbairn","year":"2017","unstructured":"Fairbairn, N., Coffin, P. O. & Walley, A. Y. Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: challenges and innovations responding to a dynamic epidemic. Int. J. Drug Policy 46, 172\u2013179 (2017).","journal-title":"Int. J. Drug Policy"},{"key":"625_CR119","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1177\/2042098617744161","volume":"9","author":"R Rzasa Lynn","year":"2018","unstructured":"Rzasa Lynn, R. & Galinkin, J. L. Naloxone dosage for opioid reversal: current evidence and clinical implications. Ther. Adv. Drug Saf. 9, 63\u201388 (2018).","journal-title":"Ther. Adv. Drug Saf."},{"key":"625_CR120","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","volume":"391","author":"JD Lee","year":"2018","unstructured":"Lee, J. D. et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet 391, 309\u2013318 (2018).","journal-title":"Lancet"},{"key":"625_CR121","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jamapsychiatry.2017.3206","volume":"74","author":"L Tanum","year":"2017","unstructured":"Tanum, L. et al. Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial. JAMA Psychiatry 74, 1197\u20131205 (2017).","journal-title":"JAMA Psychiatry"},{"key":"625_CR122","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/08897077.2018.1449053","volume":"40","author":"A Bell","year":"2019","unstructured":"Bell, A., Bennett, A. S., Jones, T. S., Doe-Simkins, M. & Williams, L. D. Amount of naloxone used to reverse opioid overdoses outside of medical practice in a city with increasing illicitly manufactured fentanyl in illicit drug supply. Subst. Abus. 40, 52\u201355 (2019).","journal-title":"Subst. Abus."},{"key":"625_CR123","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/15563650701877374","volume":"46","author":"H Schumann","year":"2008","unstructured":"Schumann, H., Erickson, T., Thompson, T. M., Zautcke, J. L. & Denton, J. S. Fentanyl epidemic in Chicago, Illinois and surrounding Cook County. Clin. Toxicol. 46, 501\u2013506 (2008).","journal-title":"Clin. Toxicol."},{"issue":"Suppl. 2","key":"625_CR124","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1365-2885.2012.01409.x","volume":"35","author":"KJ Freise","year":"2012","unstructured":"Freise, K. J., Newbound, G. C., Tudan, C. & Clark, T. P. Naloxone reversal of an overdose of a novel, long-acting transdermal fentanyl solution in laboratory Beagles. J. Vet. Pharm. Ther. 35(Suppl. 2), 45\u201351 (2012).","journal-title":"J. Vet. Pharm. Ther."},{"key":"625_CR125","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/emermed-2018-207534","volume":"36","author":"JA Greene","year":"2019","unstructured":"Greene, J. A., Deveau, B. J., Dol, J. S. & Butler, M. B. Incidence of mortality due to rebound toxicity after \u2018treat and release\u2019 practices in prehospital opioid overdose care: a systematic review. Emerg. Med. J. 36, 219\u2013224 (2019).","journal-title":"Emerg. Med. J."},{"key":"625_CR126","doi-asserted-by":"publisher","unstructured":"Karamouzian, M., Kuo, M., Crabtree, A. & Buxton, J. A. Correlates of seeking emergency medical help in the event of an overdose in British Columbia, Canada: findings from the Take Home Naloxone program. Int. J. Drug Policy. https:\/\/doi.org\/10.1016\/j.drugpo.2019.01.006 (2019).","DOI":"10.1016\/j.drugpo.2019.01.006"},{"key":"625_CR127","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1080\/10826084.2018.1555597","volume":"54","author":"CA Latkin","year":"2019","unstructured":"Latkin, C. A., Dayton, L., Davey-Rothwell, M. A. & Tobin, K. E. Fentanyl and drug overdose: perceptions of fentanyl risk, overdose risk behaviors, and opportunities for intervention among people who use opioids in Baltimore, USA. Subst. Use Misuse 54, 998\u20131006 (2019).","journal-title":"Subst. Use Misuse"},{"key":"625_CR128","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1016\/S2468-2667(18)30044-6","volume":"3","author":"MA Irvine","year":"2018","unstructured":"Irvine, M. A. et al. Distribution of take-home opioid antagonist kits during a synthetic opioid epidemic in British Columbia, Canada: a modelling study. Lancet Public Health 3, e218\u2013e225 (2018).","journal-title":"Lancet Public Health"},{"key":"625_CR129","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.drugalcdep.2017.05.001","volume":"178","author":"R McDonald","year":"2017","unstructured":"McDonald, R., Campbell, N. D. & Strang, J. Twenty years of take-home naloxone for the prevention of overdose deaths from heroin and other opioids-conception and maturation. Drug Alcohol Depend. 178, 176\u2013187 (2017).","journal-title":"Drug Alcohol Depend."},{"key":"625_CR130","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1080\/17425247.2017.1230097","volume":"14","author":"MJ Elzey","year":"2017","unstructured":"Elzey, M. J., Fudin, J. & Edwards, E. S. Take-home naloxone treatment for opioid emergencies: a comparison of routes of administration and associated delivery systems. Expert Opin. Drug Deliv. 14, 1045\u20131058 (2017).","journal-title":"Expert Opin. Drug Deliv."},{"key":"625_CR131","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1080\/14740338.2019.1613372","volume":"18","author":"HK Kim","year":"2019","unstructured":"Kim, H. K., Connors, N. J. & Mazer-Amirshahi, M. E. The role of take-home naloxone in the epidemic of opioid overdose involving illicitly manufactured fentanyl and its analogs. Expert Opin. Drug Saf. 18, 465\u2013475 (2019).","journal-title":"Expert Opin. Drug Saf."},{"key":"625_CR132","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ejphar.2014.05.044","volume":"738","author":"Z Yong","year":"2014","unstructured":"Yong, Z. et al. Nalmefene reverses carfentanil-induced loss of righting reflex and respiratory depression in rats. Eur. J. Pharm. 738, 153\u2013157 (2014).","journal-title":"Eur. J. Pharm."},{"key":"625_CR133","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001924","volume":"12","author":"C Palpacuer","year":"2015","unstructured":"Palpacuer, C. et al. Risks and benefits of nalmefene in the treatment of adult alcohol dependence: a systematic literature review and meta-analysis of published and unpublished double-blind randomized controlled trials. PLoS Med. 12, e1001924 (2015).","journal-title":"PLoS Med."},{"key":"625_CR134","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s40263-013-0101-y","volume":"27","author":"GM Keating","year":"2013","unstructured":"Keating, G. M. Nalmefene: a review of its use in the treatment of alcohol dependence. CNS Drugs 27, 761\u2013772 (2013).","journal-title":"CNS Drugs"},{"key":"625_CR135","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1159\/000494692","volume":"24","author":"P Castera","year":"2018","unstructured":"Castera, P. et al. Nalmefene, given as needed, in the routine treatment of patients with alcohol dependence: an interventional, open-label study in primary care. Eur. Addict. Res. 24, 293\u2013303 (2018).","journal-title":"Eur. Addict. Res."},{"key":"625_CR136","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1038\/s41386-019-0420-x","volume":"44","author":"JE Fragale","year":"2019","unstructured":"Fragale, J. E., Pantazis, C. B., James, M. H. & Aston-Jones, G. The role of orexin-1 receptor signaling in demand for the opioid fentanyl. Neuropsychopharmacology 44, 1690\u20131697 (2019).","journal-title":"Neuropsychopharmacology"},{"key":"625_CR137","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1021\/acschemneuro.9b00038","volume":"10","author":"S Obeng","year":"2019","unstructured":"Obeng, S. et al. Characterization of 17-cyclopropylmethyl-3,14beta-dihydroxy-4,5alpha-epoxy-6alpha-(indole-7-carboxami do)morphinan (NAN) as a novel opioid receptor modulator for opioid use disorder treatment. ACS Chem. Neurosci. 10, 2518\u20132532 (2019).","journal-title":"ACS Chem. Neurosci."},{"key":"625_CR138","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1111\/jphp.13079","volume":"71","author":"A Nozari","year":"2019","unstructured":"Nozari, A. et al. Prolonged therapy with the anticonvulsant carbamazepine leads to increased plasma clearance of fentanyl. J. Pharm. Pharm. 71, 982\u2013987 (2019).","journal-title":"J. Pharm. Pharm."},{"key":"625_CR139","doi-asserted-by":"publisher","unstructured":"Prinsloo, G., Ahamad, K. & Socias Me, Md M. Successful treatment with slow-release oral morphine following afentanyl-related overdose: a case report. Subst. Abus. https:\/\/doi.org\/10.1080\/08897077.2019.1576086 (2019).","DOI":"10.1080\/08897077.2019.1576086"},{"key":"625_CR140","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1002\/anie.201511654","volume":"55","author":"PT Bremer","year":"2016","unstructured":"Bremer, P. T. et al. Combatting synthetic designer opioids: a conjugate vaccine ablates lethal doses of fentanyl class drugs. Angew. Chem. Int. Ed. Engl. 55, 3772\u20133775 (2016).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"625_CR141","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1124\/jpet.118.253674","volume":"368","author":"MD Raleigh","year":"2019","unstructured":"Raleigh, M. D. et al. A fentanyl vaccine alters fentanyl distribution and protects against fentanyl-induced effects in mice and rats. J. Pharm. Exp. Ther. 368, 282\u2013291 (2019).","journal-title":"J. Pharm. Exp. Ther."},{"key":"625_CR142","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1038\/s41386-019-0385-9","volume":"44","author":"EA Townsend","year":"2019","unstructured":"Townsend, E. A. et al. Conjugate vaccine produces long-lasting attenuation of fentanyl vs. food choice and blocks expression of opioid withdrawal-induced increases in fentanyl choice in rats. Neuropsychopharmacology 44, 1681\u20131689 (2019).","journal-title":"Neuropsychopharmacology"},{"key":"625_CR143","doi-asserted-by":"publisher","first-page":"10489","DOI":"10.1021\/jacs.9b04872","volume":"141","author":"LC Smith","year":"2019","unstructured":"Smith, L. C. et al. Monoclonal antibodies for combating synthetic opioid intoxication. J. Am. Chem. Soc. 141, 10489\u201310503 (2019).","journal-title":"J. Am. Chem. Soc."},{"key":"625_CR144","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s00213-019-05232-0","volume":"236","author":"KR Meckel","year":"2019","unstructured":"Meckel, K. R. & Kiraly, D. D. A potential role for the gut microbiome in substance use disorders. Psychopharmacology 236, 1513\u20131530 (2019).","journal-title":"Psychopharmacology"},{"key":"625_CR145","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/jama.2019.0235","volume":"321","author":"JE Rollman","year":"2019","unstructured":"Rollman, J. E. et al. Assessment of the FDA Risk Evaluation and Mitigation Strategy for transmucosal immediate-release fentanyl products. JAMA 321, 676\u2013685 (2019).","journal-title":"JAMA"},{"key":"625_CR146","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.1340","volume":"2","author":"W Fleischman","year":"2019","unstructured":"Fleischman, W., Auth, D., Shah, N. D., Agrawal, S. & Ross, J. S. Association of a Risk Evaluation and Mitigation Strategy program with transmucosal fentanyl prescribing. JAMA Netw. Open 2, e191340 (2019).","journal-title":"JAMA Netw. Open"},{"key":"625_CR147","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1001\/jama.2019.0236","volume":"321","author":"A Sarpatwari","year":"2019","unstructured":"Sarpatwari, A. & Curfman, G. Mitigating health risks of prescription drugs: lessons from FDA oversight of opioid products. JAMA 321, 651\u2013653 (2019).","journal-title":"JAMA"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-019-0625-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-019-0625-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-019-0625-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T10:52:27Z","timestamp":1671187947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-019-0625-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,11]]},"references-count":147,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["625"],"URL":"https:\/\/doi.org\/10.1038\/s41398-019-0625-0","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,11]]},"assertion":[{"value":"25 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"282"}}